Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Cyc 116
2. Cyc-116
3. Cyc116
1. 693228-63-6
2. Cyc-116
3. Cyc116
4. Chembl482967
5. Kinome_636
6. 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine
7. 4-methyl-5-(2-((4-morpholinophenyl)amino)-pyrimidin-4-yl)thiazol-2-amine
8. 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine
9. Cyc 116
10. 2uue
11. 2c5t
12. Cyc-116(antitumor)
13. Mls006011244
14. Schembl2074998
15. Yax4981k2d
16. Cyc 116 [who-dd]
17. Ex-a753
18. Bcpp000273
19. Hms3244o11
20. Hms3244o12
21. Hms3244p11
22. Hms3654o14
23. Bcp01887
24. Zinc3950132
25. Bdbm50277583
26. Mfcd14155805
27. Nsc759498
28. Nsc800082
29. S1171
30. 4-(2-amino-4-methylthiazol-5-yl)-n-(4-morpholinophenyl)pyrimidin-2-amine
31. Akos015897897
32. Bcp9000562
33. Ccg-264845
34. Cs-0112
35. Nsc-759498
36. Nsc-800082
37. Sb16587
38. Ncgc00263204-01
39. Ncgc00263204-10
40. Ac-32833
41. As-16201
42. Hy-10558
43. Smr004703003
44. Ft-0700350
45. Sw219491-1
46. 228c636
47. A866869
48. J-515754
49. 2-[[4-morpholinophenyl]amino]-4-(2-amino-4-methylthiazole-5-yl)pyrimidine
50. [4-(2-amino-4-methyl-thiazol-5-yl)-pyrimidin-2-yl]-(4-morpholin-4-yl-phenyl)-amine
51. 2-amino-4-methyl-1,3-thiazol-5-yl)-n-[4-(morpholin-4-yl)phenyl]pyrimidin-2-amine, 5
52. 2-pyrimidinamine, 4-(2-amino-4-methyl-5-thiazolyl)-n-(4-(4-morpholinyl)phenyl)-
53. 2-pyrimidinamine,4-(2-amino-4-methyl-5-thiazolyl)-n-[4-(4-morpholinyl)phenyl]-
54. 4-(2-amino-4-methyl-5-thiazolyl)-n-[4-(4-morpholinyl)phenyl]- 2-pyrimidinamine
55. 4-(2-amino-4-methyl-5-thiazolyl)-n-[4-(4-morpholinyl)phenyl]-2-pyrimidinamine
| Molecular Weight | 368.5 g/mol |
|---|---|
| Molecular Formula | C18H20N6OS |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 368.14193046 g/mol |
| Monoisotopic Mass | 368.14193046 g/mol |
| Topological Polar Surface Area | 117 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 443 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Advanced solid tumors
Aurora kinases are enzymes that help dividing cells share their materials between two daughter cells. In many people with cancer Aurora kinase malfunctions and normal control of cell division is lost resulting in abnormal growth. CYC116 inhibits Aurora kinase may slow down the growth of cancer cells and lead to their death by apoptosis.
ABOUT THIS PAGE
41
PharmaCompass offers a list of CYC116 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right CYC116 manufacturer or CYC116 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred CYC116 manufacturer or CYC116 supplier.
PharmaCompass also assists you with knowing the CYC116 API Price utilized in the formulation of products. CYC116 API Price is not always fixed or binding as the CYC116 Price is obtained through a variety of data sources. The CYC116 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CYC116 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CYC116, including repackagers and relabelers. The FDA regulates CYC116 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CYC116 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A CYC116 supplier is an individual or a company that provides CYC116 active pharmaceutical ingredient (API) or CYC116 finished formulations upon request. The CYC116 suppliers may include CYC116 API manufacturers, exporters, distributors and traders.
CYC116 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CYC116 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CYC116 GMP manufacturer or CYC116 GMP API supplier for your needs.
A CYC116 CoA (Certificate of Analysis) is a formal document that attests to CYC116's compliance with CYC116 specifications and serves as a tool for batch-level quality control.
CYC116 CoA mostly includes findings from lab analyses of a specific batch. For each CYC116 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CYC116 may be tested according to a variety of international standards, such as European Pharmacopoeia (CYC116 EP), CYC116 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CYC116 USP).
